Review top news and interview highlights from the week ending November 4, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Abeona has announced topline results from its phase 3 VIITAL study of EB-101.
Updated data from the ALTITUTE trial were presented at the 55th ARS meeting in Pasadena, CA.
The vice president of Public Policy & Advocacy of the Muscular Dystrophy Association discussed the organization’s goals and strategies in educating regulatory decision-makers.
Data from the first 2 patients were presented at the IWWM 2022 meeting.
In this feature, CGTLive highlights the PROVIDE trial of PR001 for Gaucher Awareness Month.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.